Patents by Inventor Christophe Filippi

Christophe Filippi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-CYTOKINS ENGRAFTED PROTEINS AND METHODS OF US IN THE TREATMENT OF CANCER
    Publication number: 20240141022
    Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.
    Type: Application
    Filed: December 26, 2023
    Publication date: May 2, 2024
    Inventors: Jonathan DEANE, Yaiza DIAZ-DE-DURANA, Michael DIDONATO, Christophe FILIPPI, Glen SPRAGGON
  • Antibody-cytokine engrafted proteins and methods of use for immune related disorders
    Patent number: 11930837
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE FOR IMMUNE RELATED DISORDERS
    Publication number: 20220346415
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Application
    Filed: July 18, 2022
    Publication date: November 3, 2022
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE FOR IMMUNE RELATED DISORDERS
    Publication number: 20220039441
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 10, 2022
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • Antibody-cytokine engrafted proteins and methods of use for immune related disorders
    Patent number: 11122825
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: September 21, 2021
    Assignee: Novartis AG
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE IN THE TREATMENT OF CANCER
    Publication number: 20200270334
    Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.
    Type: Application
    Filed: May 22, 2018
    Publication date: August 27, 2020
    Inventors: Jonathan Deane, Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Glen Spraggon
  • ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE FOR IMMUNE RELATED DISORDERS
    Publication number: 20200113974
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Application
    Filed: May 22, 2018
    Publication date: April 16, 2020
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shellly Meeusen, Glen Spraggon